November 30, 2009 — Recommendations for primary care clinicians regarding the diagnosis and treatment of nephrotic syndrome in adults are reviewed in the November 15 issue of the American Family ...

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

Idiopathic nephrotic syndrome is the most common disorder of glomerular function in pediatrics. [1] Approximately 40% of children diagnosed with idiopathic nephrotic syndrome will have a relapsing ...

Nephrotic syndrome is characterized by a set of signs and symptoms including proteinuria, low protein levels in the blood, hypercholesterolemia, hypertriglyceridemia, and edema. It may be caused by ...

In five children a nephrotic syndrome developed within one month (three cases), 11 months, and 10 years of the onset of diabetes mellitus. The syndrome, which responded to steroid therapy, was ...

A clinical and basic research being conducted on childhood nephrotic syndrome identified the different types of genetic mutations linked to nephrotic syndrome. The aim is to identify the genetic ...

Corstasis Therapeutics has announced a collaboration with Cardiovascular Logistics (CVL) to advance the adoption and ...

The nephrotic syndrome is affecting many people across the United States. It is actually a kidney disorder that leads your body to release way too much protein in the urine. It is a syndrome that is ...

Are you searching for medications to treat 'Childhood Nephrotic Syndrome'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Childhood Nephrotic ...

Better understanding of the genetic basis of Nephrotic Syndrome can aid the hunt for therapeutic targets for this chronic kidney disease. Investigations into the different genetic pathways in steroid ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company advancing innovative outpatient therapies for cardiovascular and renal disease, today announced that it is working with ...